Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Head and Neck Cancer

  Free Subscription


12.11.2018

5 Ann Otol Rhinol Laryngol
4 Anticancer Res
1 BMC Cancer
1 Br J Oral Maxillofac Surg
1 Clin Cancer Res
2 Clin Nucl Med
5 Dis Esophagus
4 Gastrointest Endosc
1 Head Neck
1 Histopathology
1 HNO
2 Int J Pediatr Otorhinolaryngol
1 Int J Radiat Oncol Biol Phys
21 Oral Oncol
4 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Otol Rhinol Laryngol

  1. BROWN CS, Abi Hachem R, Pendse A, Madden JF, et al
    Low-Grade Papillary Schneiderian Carcinoma of the Sinonasal Cavity and Temporal Bone.
    Ann Otol Rhinol Laryngol. 2018;127:974-977.
    PubMed     Text format     Abstract available

  2. CAO Y, Sun G
    Surgical Treatment Modalities for Iatrogenic Anterior Glottic Stenosis.
    Ann Otol Rhinol Laryngol. 2018;127:946-952.
    PubMed     Text format     Abstract available

  3. CHAN MH, Wang F, Mang WK, Tse LA, et al
    Sex Differences in Time Trends on Incidence Rates of Oropharyngeal and Oral Cavity Cancers in Hong Kong.
    Ann Otol Rhinol Laryngol. 2018;127:895-902.
    PubMed     Text format     Abstract available

  4. KINZINGER MR, Strong EB, Bernard J, Steele TO, et al
    Intralesional Bevacizumab for the Treatment of Recurrent Sinonasal Hemangioma.
    Ann Otol Rhinol Laryngol. 2018;127:969-973.
    PubMed     Text format     Abstract available

  5. BEST AR, Halum SL, Parker NP
    Current Indications for Transnasal Esophagoscopy: An American Broncho-Esophagological Association Survey.
    Ann Otol Rhinol Laryngol. 2018;127:926-930.
    PubMed     Text format     Abstract available


    Anticancer Res

  6. BABA J, Kioi M, Akimoto K, Nagashima Y, et al
    Atypical Protein Kinase C lambda/iota Expression Is Associated with Malignancy of Oral Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:6291-6297.
    PubMed     Text format     Abstract available

  7. KIM SH, Kang JG, Kim CS, Ihm SH, et al
    Evodiamine Suppresses Survival, Proliferation, Migration and Epithelial-Mesenchymal Transition of Thyroid Carcinoma Cells.
    Anticancer Res. 2018;38:6339-6352.
    PubMed     Text format     Abstract available

  8. ISOZAKI Y, Yasuda S, Akutsu Y, Shimada H, et al
    Salvage Carbon-ion Radiotherapy for Isolated Lymph Node Recurrence Following Curative Resection of Esophageal Cancer.
    Anticancer Res. 2018;38:6453-6458.
    PubMed     Text format     Abstract available

  9. KATSURAHARA K, Shiozaki A, Fujiwara H, Konishi H, et al
    Relationship Between Postoperative CRP and Prognosis in Thoracic Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:6513-6518.
    PubMed     Text format     Abstract available


    BMC Cancer

  10. TOMASETTI M, Re M, Monaco F, Gaetani S, et al
    MiR-126 in intestinal-type sinonasal adenocarcinomas: exosomal transfer of MiR-126 promotes anti-tumour responses.
    BMC Cancer. 2018;18:896.
    PubMed     Text format     Abstract available


    Br J Oral Maxillofac Surg

  11. KUMAR K, Kumar S, Mehrotra D, Tiwari SC, et al
    Prospective evaluation of psychological burden in patients with oral cancer.
    Br J Oral Maxillofac Surg. 2018 Nov 6. pii: S0266-4356(18)30312.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  12. CLUMP DA, Pickering CR, Skinner HD
    Predicting Outcome in Head and Neck Cancer: miRNAs with potentially big effects.
    Clin Cancer Res. 2018 Nov 9. pii: 1078-0432.CCR-18-3078.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  13. SANLI Y, Zukotynski K, Mittra E, Chen DL, et al
    Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer.
    Clin Nucl Med. 2018;43:e439-e452.
    PubMed     Text format     Abstract available

  14. GAO R, Gao S, Jia X, Wang H, et al
    Ectopic Papillary Thyroid Carcinoma Mimicking Esophageal Cancer in FDG PET: A Case Report.
    Clin Nucl Med. 2018 Nov 3. doi: 10.1097/RLU.0000000000002377.
    PubMed     Text format     Abstract available


    Dis Esophagus

  15. BELMOUHAND M, Svendsen LB, Kofoed SC, Normann G, et al
    Recurrence following curative intended surgery for an adenocarcinoma in the gastroesophageal junction: a retrospective study.
    Dis Esophagus. 2018;31.
    PubMed     Text format     Abstract available

  16. STIER MW, Lodhia N, Jacobs J, Nozicka D, et al
    Perceptions of risk and therapy among patients with Barrett's esophagus: a patient survey study.
    Dis Esophagus. 2018;31.
    PubMed     Text format     Abstract available

  17. KAHN A, Al-Qaisi M, Kommineni VT, Callaway JK, et al
    Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
    Dis Esophagus. 2018;31.
    PubMed     Text format     Abstract available

  18. KUMABE A, Fukada J, Kota R, Koike N, et al
    Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Dis Esophagus. 2018;31.
    PubMed     Text format     Abstract available

  19. HARRISON M, Allen JE, Gorrepati VS, Lopez-Jamar JME, et al
    Management of Barrett's esophagus with low-grade dysplasia.
    Dis Esophagus. 2018;31.
    PubMed     Text format     Abstract available


    Gastrointest Endosc

  20. ORTIZ-FERNANDEZ-SORDO J, Ragunath K
    Barrett's ablation: blowing hot, blowing cold.
    Gastrointest Endosc. 2018;88:804-806.
    PubMed     Text format    

  21. NAGPAL SJS, Yi JE, Wong Kee Song LM, Topazian MD, et al
    Mucinous adenocarcinoma of unknown primary presenting with dysphagia.
    Gastrointest Endosc. 2018;87:1582-1583.
    PubMed     Text format    

  22. SIU W, Murray GI, McKinlay A, Phull P, et al
    Extensive esophageal papillomatosis after chemoradiotherapy for squamous cell carcinoma.
    Gastrointest Endosc. 2018;87:1581-1582.
    PubMed     Text format    

  23. JIANG K, Lauwers GY
    The dawn of a new era: performance measurement for the pathologic diagnosis of Barrett's esophagus-associated dysplasia.
    Gastrointest Endosc. 2018;88:816-817.
    PubMed     Text format    


    Head Neck

  24. TRUONG AT, Truong DT, Rahlfs TF
    TRS score: A proposed mnemonic for airway assessment and management in patients with head and neck cancers.
    Head Neck. 2018 Nov 2. doi: 10.1002/hed.25502.
    PubMed     Text format    


    Histopathology

  25. NAKAGURO M, Urano M, Suzuki H, Yamada K, et al
    Low-grade intraductal carcinoma of the salivary gland with prominent oncocytic change: a newly described variant.
    Histopathology. 2018;73:314-320.
    PubMed     Text format     Abstract available


    HNO

  26. LABAN S, Doescher J, Busch CJ, Wollenberg B, et al
    [Immunotherapy highlights of the ASCO annual meeting 2018 for head and neck cancers].
    HNO. 2018 Nov 6. pii: 10.1007/s00106-018-0586-2. doi: 10.1007/s00106-018-0586.
    PubMed     Text format     Abstract available


    Int J Pediatr Otorhinolaryngol

  27. MCCORMICK AA, Tarchichi T, Azbell C, Grunwaldt L, et al
    Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.
    Int J Pediatr Otorhinolaryngol. 2018;113:34-37.
    PubMed     Text format     Abstract available

  28. APPACHI S, Meleca JB, Krakovitz P
    Metastasis of Ewing's sarcoma to the thyroid gland: A case report.
    Int J Pediatr Otorhinolaryngol. 2018;113:26-28.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  29. JI Z, Jiang Y, Tian S, Guo F, et al
    The Effectiveness and Prognostic Factors of CT-guided Radioactive Iodine-125 Seed Implantation for the Treatment of Recurrent Head and Neck Cancer after External Beam Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2018 Nov 1. pii: S0360-3016(18)33923.
    PubMed     Text format     Abstract available


    Oral Oncol

  30. SPECTOR ME, Rosko AJ, Swiecicki PL, Chad Brenner J, et al
    From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer.
    Oral Oncol. 2018;86:200-205.
    PubMed     Text format     Abstract available

  31. ANDREASSEN CN, Eriksen JG, Jensen K, Hansen CR, et al
    IMRT - Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer.
    Oral Oncol. 2018;86:91-99.
    PubMed     Text format     Abstract available

  32. GENSHEIMER MF, Le QT
    Adaptive radiotherapy for head and neck cancer: Are we ready to put it into routine clinical practice?
    Oral Oncol. 2018;86:19-24.
    PubMed     Text format     Abstract available

  33. QIAO X, Liu W, Cao Y, Miao C, et al
    Performance of different imaging techniques in the diagnosis of head and neck cancer mandibular invasion: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:150-164.
    PubMed     Text format     Abstract available

  34. CHUANG HC, Chou MH, Chien CY, Chuang JH, et al
    Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells.
    Oral Oncol. 2018;86:141-149.
    PubMed     Text format     Abstract available

  35. ZANDBERG DP, Cullen K, Bentzen SM, Goloubeva OG, et al
    Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
    Oral Oncol. 2018;86:132-140.
    PubMed     Text format     Abstract available

  36. SHAIKH MH, Idris A, Johnson NW, Fallaha S, et al
    Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
    Oral Oncol. 2018;86:105-112.
    PubMed     Text format     Abstract available

  37. DO JH, Yoon IJ, Cho YK, Ahn JS, et al
    Comparison of hospital based and home based exercise on quality of life, and neck and shoulder function in patients with spinal accessary nerve injury after head and neck cancer surgery.
    Oral Oncol. 2018;86:100-104.
    PubMed     Text format     Abstract available

  38. LIU W, Chen S, Yang W
    The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma.
    Oral Oncol. 2018 Nov 2. pii: S1368-8375(18)30404.
    PubMed     Text format    

  39. GUJRAL DM, Nutting CM
    Patterns of failure, treatment outcomes and late toxicities of head and neck cancer in the current era of IMRT.
    Oral Oncol. 2018;86:225-233.
    PubMed     Text format     Abstract available

  40. KASHYAP T, Pramanik KK, Nath N, Mishra P, et al
    Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3beta signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Oral Oncol. 2018;86:234-243.
    PubMed     Text format     Abstract available

  41. YANG WF, Wong MCM, Thomson PJ, Li KY, et al
    The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:81-90.
    PubMed     Text format     Abstract available

  42. KIM M, Kim HK, Kim HI, Kim EH, et al
    Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
    Oral Oncol. 2018;86:48-52.
    PubMed     Text format     Abstract available

  43. BONOMI MR, Blakaj A, Blakaj D
    Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies.
    Oral Oncol. 2018;86:301-306.
    PubMed     Text format     Abstract available

  44. EVANS M, Beasley M
    Target delineation for postoperative treatment of head and neck cancer.
    Oral Oncol. 2018;86:288-295.
    PubMed     Text format     Abstract available

  45. HARTMAN DJ, Ahmad F, Ferris RL, Rimm DL, et al
    Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;86:278-287.
    PubMed     Text format     Abstract available

  46. PENG L, Chen YP, Xu C, Tang LL, et al
    A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
    Oral Oncol. 2018;86:258-265.
    PubMed     Text format     Abstract available

  47. FUJIWARA T, Eguchi T, Sogawa C, Ono K, et al
    Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
    Oral Oncol. 2018;86:251-257.
    PubMed     Text format     Abstract available

  48. SEGRELLES C, Paramio JM, Lorz C
    The transcriptional co-activator YAP: A new player in head and neck cancer.
    Oral Oncol. 2018;86:25-32.
    PubMed     Text format     Abstract available

  49. GARNEAU JC, Bakst RL, Miles BA
    Hypopharyngeal cancer: A state of the art review.
    Oral Oncol. 2018;86:244-250.
    PubMed     Text format     Abstract available

  50. ESKANDER A, Blakaj DM, Dziegielewski PT
    Decision making in advanced larynx cancer: An evidenced based review.
    Oral Oncol. 2018;86:195-199.
    PubMed     Text format     Abstract available


    Radiother Oncol

  51. ROONEY KP, Miah AB, Bhide SA, Guerrero-Urbano MT, et al
    Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.
    Radiother Oncol. 2018;127:43-48.
    PubMed     Text format     Abstract available

  52. LINGE A, Schotz U, Lock S, Lohaus F, et al
    Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
    Radiother Oncol. 2018;127:27-35.
    PubMed     Text format     Abstract available

  53. CRISPIN-ORTUZAR M, Apte A, Grkovski M, Oh JH, et al
    Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [(18)F]-Fluorodeoxyglucose positron emission tomography radiomics features.
    Radiother Oncol. 2018;127:36-42.
    PubMed     Text format     Abstract available

  54. TOPKAN E, Yildirim BA
    Epoetin receptor status may alter the outcomes in head and neck cancers treated with radiotherapy and darbepoetin-alpha.
    Radiother Oncol. 2018 Nov 7. pii: S0167-8140(18)33397.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: